Michael Wood is on the Board of Directors of Neurovation Labs and is an advising member. Dr. Wood received his B.S. in Environmental Health from Oakland University in 1992 and his Ph.D. in Pharmacology/toxicology from Duke University in 1996. Following postdoctoral appointments at Harvard and Eli Lilly, he worked in CNS drug discovery at AstraZeneca for 18 years, holding a variety of scientific positions – section head, project leader – before moving into strategic roles – target team leader and collaboration director. He has directed or facilitated dozens of drug discovery projects across a variety of CNS indications at all stages of discovery. He recently established an independent drug discovery consultancy, Neupharm LLC. He has held executive positions in with the American Society of Pharmacology and Experimental Therapeutics for the last eight years and recently co-organized a colloquium on academic drug discovery in collaboration with the Academic Drug Discovery Consortia.